Abstract 37P
Background
Atypical Ductal Hyperplasia (ADH) is a pre-malignant high-risk breast lesion, with morphological features similar to that of ductal carcinoma in situ (DCIS). The WHO diagnosis of ADH is defined as cytonuclear and architectural atypia <2mm in size. The current standard management is surgical excision, due to its reported 10-30% risk of upgrade to breast cancer. However, an increasingly observed alternative management utilizes a conservative approach with annual radiological follow up, quoting lower upgrade risks of 3-5%. Indications for conservative follow-up include low-risk patients or intial biopsy with vacuum assistance. Our primary aim is to investigate the ADH upgrade risk in a Singapore cohort, with a secondary goal of comparing upgrade cancer rates in upfront surgical management versus upgrade rates on conservative surveillance, to discuss feasibility of adopting a primarily conservative approach for the population.
Methods
A retrospective study was performed of 221 patients diagnosed with ADH between January 2013 to June 2023 in a tertiary institute. Initial biopsy histology, management approach and patient outcomes were evaluated. Outcome was measured by upgrade to early breast cancer. Odds ratio & relative risk was used to adjust for demographics, risk profile and biopsy methods.
Results
221 patients were diagnosed with ADH on biopsy, of whom 8 opted for surveillance. There was an overall upgrade risk of 31.22%, with 75.36% of upgrade histology being DCIS. Of all upgrades, 97.10% were diagnosed on upfront surgical excision after a mean period of 39 days, while 2.9% were diagnosed after a period of conservative surveillance. Of the 8 patients opting for conservative management, 1 patient received repeat biopsy and another 2 patients received surgical excision after a mean period of 268 days.
Conclusions
Our findings of a 31% upgrade risk of ADH to early breast cancer, consistent with that of reported literature, still support the case for upfront surgical excision of ADH. We recommend upfront surgical excision of ADH once discovered on initial biopsy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
63P - Efficacy and safety of eribulin plus carboplatin combination for HER2-negative metastatic breast cancer
Presenter: Mengqian Ni
Session: Poster Display
Resources:
Abstract
64P - Unmet needs following metastatic breast cancer in a middle-income Asian country
Presenter: Nirmala Bhoo-Pathy
Session: Poster Display
Resources:
Abstract
66P - Utidelone-based therapy in metastatic solid tumors after failure of standard therapies: A prospective, multicenter, single-arm trial
Presenter: Jianjun Zhang
Session: Poster Display
Resources:
Abstract
67P - Efficacy and safety of trastuzumab biosimilar in HER2+ve metastatic breast cancer: A multicenter phase III study
Presenter: krishna Mohan
Session: Poster Display
Resources:
Abstract
68P - Neratinib in combination with fulvestrant and or palbociclib can overcome endocrine resistance in HER2-low/ ER+ breast cancer
Presenter: Maryam Arshad
Session: Poster Display
Resources:
Abstract
69P - A multicenter, retrospective, real-world study of inetetamab combined with pyrotinib and vinorelbine as treatment for HER2-positive metastatic breast cancer
Presenter: Nan Jin
Session: Poster Display
Resources:
Abstract
70P - Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
Presenter: Kenichi Inoue
Session: Poster Display
Resources:
Abstract
71P - Efficacy and safety of disitamab vedotin after trastuzumab for HER2 -positive breast cancer: A real-world data of retrospective study
Presenter: Chao Li
Session: Poster Display
Resources:
Abstract
72P - Real-world data on the efficacy of T-DM1 biosimilar for the treatment of HER2-positive metastatic breast cancer patients: Outcomes from a single center retrospective study in India
Presenter: Kaushal Patel
Session: Poster Display
Resources:
Abstract
73TiP - Global phase III studies evaluating vepdegestrant in estrogen receptor (ER)+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer: VERITAC-2 and VERITAC-3
Presenter: Hiroji Iwata
Session: Poster Display
Resources:
Abstract